

Median Relative Tumor Volume [%]
350
300
250
200
150
100
50
0
0 5 10 15 20 25 30 35 40 45 50 55 60
Days after Randomisation
Vehicle control
MM-121; 600 µg/mouse/day ip; Days 0,3,6,...63
200
50

Fig. 1



Percent change in tumor volume
(compared to day 6)
430
380
330
280
230
180
130
80
30
-20
8
14
16
21
23
28
30
38
42
45
balb/c mice mp
balb/c mice sc
balb/c MM121 600ug mp
balb/c MM121 600ug sc

Fig. 2



MDA -MB231
Paclitaxel and MM121 combination
PBS
MM121 (150µg/mouse)
paclitaxel (5mpk)
MM121 + paclitaxel
Volume mm3
400.0
300.0
200.0
100.0
0.0
0
10
20
30
Days

Fig. 3



MDA MB231_MM121 + cetuximab + paclitaxel
PBS
MM121 300µg
cetuximab 2mpk
paclitaxel 10mpk
MM121 + cetuximab + paclitaxel
MM121 + cetuximab
Tumor Volume
600.0
500.0
400.0
300.0
200.0
100.0
0.0
28
32
36
39
43
46
49
53
Day

Fig. 4A



MDA MB231 MM121 + erlotinib + paclitaxel
PBS
MM121 300µg
erlotinib 50mpk
MM121 + erlotinib
paclitaxel 10mpk
MM121 + erlotinib + paclitaxel
Tumor Volume
600.0
500.0
400.0
300.0
200.0
100.0
0.0
28
32
36
39
43
46
49
53
Day

Fig. 4B